LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
They experience these feelings by repeated contact through the six sense-bases; feeling conditions craving; craving conditions clinging; clinging conditions becoming; becoming conditions birth; birth conditions aging and death, sorrow, lamentation, sadness and distress. Similarly, the Madhupiṇḍikasutta (MN 18) also contains the following passage:Eye consciousness arises dependent on the eye and sights. The meeting of the three is contact. Contact is a condition for feeling. What you feel, you perceive. What you perceive, you think about. What you think about, you proliferate (papañca). What you proliferate about is the source from which a person is beset by concepts of identity that emerge from the proliferation of perceptions. This occurs with respect to sights known by the eye in the past, future, and present. [The same process is then repeated with the other six sense bases.]The Mahānidānasutta (DN 15) and its Chinese parallels such as DA 13 describe a unique version which is dubbed the "looped version" by Bucknell (DN 14 also has a similar looped chain but it adds the six sense fields after name and form):Name and form are conditions for consciousness. Consciousness is a condition for name and form. Name and form are conditions for contact. Contact is a condition for feeling. Feeling is a condition for craving. Craving is a condition for grasping. Grasping is a condition for continued existence. Continued existence is a condition for rebirth. Rebirth is a condition for old age and death, sorrow, lamentation, pain, sadness, and distress to come to be.
== Biography == Franciszek Gajowniczek, a Roman Catholic, was born in Strachomin near Mińsk Mazowiecki. After the reconstitution of sovereign Poland, he moved to Warsaw in 1921, married, and had two sons. He was a professional soldier, a Polish army sergeant, who took part in the defense of Wieluń as well as Warsaw in September 1939 during the 1939 invasion of Poland by Nazi Germany. After the Battle of Modlin Gajowniczek was captured by the Gestapo in Zakopane while crossing the border into Slovakia and sentenced to forced labour in Tarnów.
Previously, many studies used Mass Spectrometry (MS) in different fragmentation modes to detect AMPylated peptides. In responses to the distinctive fragmentation techniques, AMPylated protein sequences disintegrated at different parts of AMP. While electron transfer dissociation (ETD) creates minimum fragments and less complicated spectra, collision-induced dissociation (CID) and high-energy collision (HCD) fragmentation generate characteristic ions suitable for AMPylated proteins identification by generating multiple AMP fragments. Due to AMP's stability, peptide fragmentation spectra is easy to read manually or with search engines. Inhibitors of protein AMPylation with inhibitory constant (Ki) ranging from 6 - 50 μM and at least 30-fold selectivity versus HypE have been discovered.
1 element (tin) has 10 stable isotopes 5 elements have 7 stable isotopes apiece 7 elements have 6 stable isotopes apiece 11 elements have 5 stable isotopes apiece 9 elements have 4 stable isotopes apiece 5 elements have 3 stable isotopes apiece 16 elements have 2 stable isotopes apiece 26 elements have 1 single stable isotope. These last 26 are thus called monoisotopic elements. The mean number of stable isotopes for elements which have at least one stable isotope is 251/80 = 3.1375.
As of 2025, many companies are researching and manufacturing new insulin analogues. These insulins are usually designed to be either ultra-short-acting or ultra-long-acting. Insulin degludec, an ultra-long-acting insulin analog, was developed by Novo Nordisk and approved by the FDA in 2015. Insulin degludec has an extended duration of action, lasting up to 42 hours, offering greater flexibility in dosing schedules. In March 2024, insulin icodec was approved for medical use in Canada. The same month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion, recommending the granting of marketing authorization for Awiqli, under which insulin icodec is marketed. Following the CHMP's recommendation, insulin icodec was approved for medical use in the European Union in May 2024. Insulin icodec has a plasma half-life more than eight days (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.
Sources: en.wikipedia.org
Svante Cornell argued that although Tagliavini's report did blame Georgia for starting the war, that "should not be confused with the question of responsibility." He also criticised the argument that agreements did not allow Georgia to use force, because the mission did not analyze whether Russian or South Ossetian use of force still bound Georgia to the non-use of force. Cornell also criticised the report since it did not include evidence amassed by researcher Andrey Illarionov. Cornell also wrote in another article that the report was "far more devastating in its dismissal of Russia's justification for its invasion—in fact surprisingly so for an EU product." Georgian president Saakashvili said that the commission "said even more truth than I could ever imagine." He later said that he would still take the same action as he did on 7 August 2008 and he did not regret anything. The report caused the Georgian opposition to protest against President Saakashvili. The Wall Street Journal wrote that the report "shrinks from drawing the obvious conclusion, which is that this is a war the Kremlin wanted, schemed for, and got." On 8 October 2009, NATO Secretary General Anders Fogh Rasmussen declared that the report would not influence Georgian and Ukrainian membership of NATO. On 12 October 2009, Yulia Latynina, Russian journalist, wrote that the commission actually did not establish who was responsible for the war and which of the sides was lying.
==== Chronic circadian rhythm sleep disorders (CRSD) ==== In the management of circadian rhythm disorders such as delayed sleep phase disorder (DSPD), the timing of light exposure is critical. Light exposure administered to the eyes before or after the nadir of the core body temperature rhythm can affect the phase response curve. Use upon awakening may also be effective for non-24-hour sleep–wake disorder. Some users have reported success with lights that turn on shortly before awakening (dawn simulation). Evening use is recommended for people with advanced sleep phase disorder. Some, but not all, totally blind people whose retinae are intact, may benefit from light therapy.
==== Harry Potter partnership ==== In August 2026, Tim Horton announced that it would be releasing a series of themed menu items to mark the 25th anniversary of the release of the first film of the Harry Potter movie franchise as part of its “Back to Hogwarts with Harry Potter” campaign. Menu items included themed donuts and drinks. Harry Potter-themed "quiz nights" were also held at selected stores across Canada.
Ammonium bicarbonate is an inorganic compound with formula (NH4)HCO3. It is the bicarbonate salt of the ammonium ion. It is a colourless solid that degrades readily to carbon dioxide, water and ammonia.
Sources: en.wikipedia.org
== SB == Sb – (s) Antimony (Latin Stibium) SbA - Stibarsen, an alloy of antimony and arsenic SB (i) Sexy Bitch Sexy Bastard Sexy Boy (disambiguation) (s) Solomon Islands (ISO 3166 digram) (i) Special Warfare Boat Operator SBA (i) Santa Barbara Airport Simulation-Based Acquisition Small Business Administration Sovereign Base Area Student bar association SBB – (i) German for the Swiss Federal Railways SBC (i) Sensotronic Brake Control Single-Board Computer Southern Baptist Convention Sun Belt Conference (US college sports) SBCCOM – (p) U.S. Army Soldier and Biological Chemical Command (disbanded 2003) SBCS – (i) Single-Byte Character Set SBCT – (i) Stryker Brigade Combat Team SBD (s) Solomon Islands dollar (ISO 4217 currency code) Silent But Deadly SBP (i) Samahang Basketbol ng Pilipinas (Filipino, "Basketball Federation of the Philippines") U.S. School Breakfast Program Society of Business Practitioners State Bank of Pakistan SBS (i) Special Boat Service Special Broadcasting Service Seoul Broadcasting System SBW (i) Sonny Bill Williams (New Zealand dual-code rugby player)
Michael Francis Compton (b. 25 November 1940) [with Doreen Crick] Gabrielle Anne (b. 15 July 1951) [with Odile Crick] Jacqueline Marie-Therese [later Nichols] (b. 12 March 1954, d. 28 February 2011) [with Odile Crick]; Crick died of colon cancer on the morning of 28 July 2004 at the University of California, San Diego (UCSD) Thornton Hospital in La Jolla; he was cremated and his ashes were scattered into the Pacific Ocean. A public memorial was held on 27 September 2004 at the Salk Institute, La Jolla, near San Diego, California; guest speakers included James Watson, Sydney Brenner, Alex Rich, Seymour Benzer, Aaron Klug, Christof Koch, Pat Churchland, Vilayanur Ramachandran, Tomaso Poggio, Leslie Orgel, Terry Sejnowski, his son Michael Crick, and his younger daughter Jacqueline Nichols. A private memorial for family and colleagues was held on 3 August 2004. Crick's Nobel Prize medal and diploma from the Nobel committee was sold at Heritage Auctions in June 2013 for $2,270,000. It was bought by Jack Wang, the CEO of Chinese medical company Biomobie. 20% of the sale price of the medal was donated to the Francis Crick Institute in London.
Ro 28-2653 is highly selective for MMP-2, MMP-9 and membrane type 1 (MT-1)-MMP. It is an antitumor and antiangiogenic agent with oral bioavailability. Inhibition of TACE and MMP-1 are linked to the musculoskeletal side effects seen in hydroxamate metalloproteinase inhibitors, but this compound spares the enzymes. It has been shown to diminish tumor growth in nasal cancer in rats as well as prostate cancer cell cultures. The compound only has moderate effect on mice's adipose tissue and no alteration on joints. Based on this, it is concluded that class of inhibitors is less likely to trigger neuromuscular adverse effects. On the active site of the structure is a pyrimidinetrione chelation and the phenyl and piperidynil section occupy the S1’ and S2’ binding pockets of MMP-8. Compound 556052-30-3 is similar to Ro 28-2653 but incorporates a 4-((2-methylquinolin-4-yl)methoxy)phenyl sidechain that is TACE selective. 5-(spiropyrrolidin-5-yl)pyrimidinetrione is a compound named 848773-43-3 that is a potent MMP-2, MMP-9 and MMP-13 inhibitor that spares MMP-1 and TACE. By substituting 1,3,4-oxadiazol-2-yl heteroaryl at C-4’ of the diphenylether segment to accomplish MMP-13 selectivity over MT-1 MMP, made the compound 420121-84-2. The compound has IC50 (half maximal inhibitory concentration) of 1 nM for MMP-13. I125-radioable pyrimidinetriones that have similar structure have been made to be used in MMP-9 elevated atherosclerosis and elevated MMP-2 and MMP-9 cancers. This class of MMP inhibitors is easy to synthesize and are potent enough for clinical valuation.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.